Avoro Capital Advisors LLC 13D and 13G filings for BioCryst Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-15 09:31 am Sale | 2025-03-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | Avoro Capital Advisors LLC | 8,700,000 4.200% | -4,350,000 (-33.33%) | Filing |
| 2024-02-14 09:02 am Purchase | 2023-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | Avoro Capital Advisors LLC | 13,050,000 6.400% | 13,050,000 (New Position) | Filing |